WO2017146486A1 - Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus - Google Patents

Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus Download PDF

Info

Publication number
WO2017146486A1
WO2017146486A1 PCT/KR2017/002001 KR2017002001W WO2017146486A1 WO 2017146486 A1 WO2017146486 A1 WO 2017146486A1 KR 2017002001 W KR2017002001 W KR 2017002001W WO 2017146486 A1 WO2017146486 A1 WO 2017146486A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
preventing
prostatic hyperplasia
pharmaceutical composition
Prior art date
Application number
PCT/KR2017/002001
Other languages
English (en)
Korean (ko)
Inventor
신현규
이미영
서창섭
전우영
하혜경
Original Assignee
한국한의학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국한의학연구원 filed Critical 한국한의학연구원
Publication of WO2017146486A1 publication Critical patent/WO2017146486A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)

Definitions

  • the present invention is Morus alba Linne Extract and Curcumae Rhizoma ) relates to a composition for the prevention or treatment of prostatic hyperplasia comprising an extract, specifically, a pharmaceutical composition, a food composition for preventing or treating prostate hyperplasia comprising an extract of the baekryepi or fractions thereof and an extract of the extract or its fractions as an active ingredient It relates to a quasi-drug composition, and to a method for preventing or treating enlarged prostate using the pharmaceutical composition.
  • Prostatic hyperplasia is a benign tumor commonly found in middle-aged men in their 40s and 50s.
  • the prostate is enlarged, which causes pressure on the posterior urethra.
  • One of the most common diseases in middle-aged men, usually beginning in their 40s, 50% in their 50s, 60% in their 60s, and 70% in their 70s have prostatic hyperplasia. The number of is gradually increasing proportionally.
  • sympathetic blockers that relieve smooth muscle tone, anti-male hormones that inhibit abnormal proliferation of the prostate epithelium, and 5 ⁇ -reductase inhibitors are used to improve temporary symptoms. It is used for prevention purposes.
  • the sympathetic blocker acts to lower blood pressure, so it is limited to patients with hypotension, and artificially regulates nerves, resulting in bowel movements, resulting in constipation or chronic fatigue.
  • anti-male hormones can also cause side effects such as decreased libido and erectile dysfunction.
  • Finasteride is a representative 5 ⁇ -reductase inhibitor and is commercially available under the trade name Proscar or Propecia. Finasteride inhibits the production of DHT (Dihydrotestosterone), which reduces androgen activity in the scalp, and in the prostate, reduces the weight and volume of the prostate, inhibiting the development of enlarged prostate and reducing the risk of developing prostate cancer (Robaire B et. al., 2006, Molecular and Cellular Endocrinology, 250 (1-2): 190-5.).
  • DHT Dihydrotestosterone
  • finasteride Due to the superiority of these effects, development of related technologies using finasteride, such as a novel method for preparing high purity finasteride (Korean Patent No. 0483136), a composition for treating hair loss including polymerized finasteride nanoparticles (Korea Patent Publication No. 2015-0046332), etc. It is done.
  • a novel method for preparing high purity finasteride Korean Patent No. 0483136
  • a composition for treating hair loss including polymerized finasteride nanoparticles Korean Patent Publication No. 2015-0046332
  • side effects that increase the incidence of breast cancer in men and cause sexual dysfunction have been reported and require caution (Medicines and Healthcare products Regulatory Agency Drug Safety Update, 2009; Mella JM et al., 2010), Archives of Dermatology 146 (10): 1141-50.).
  • Morus alba Linne is a medicinal herb made from the mulberry of the mulberry family or from the roots of the same plant. It has been proven to be effective in treating atherosclerosis and essential hypertension. In addition, it has been known that the extract may be used for the treatment of depression (Korean Patent Publication No. 2009-0116547), the effect on the enlarged prostate has not been found.
  • the present inventors have completed the present invention by confirming that the composition containing the extract of the lettuce extract, which is a natural herb, has an excellent effect on prostate hyperplasia, as a result of earnest research efforts to develop a prostate hypertrophy having no side effects and excellent efficacy.
  • One object of the present invention is Morus It is to provide a pharmaceutical composition for the prevention or treatment of enlarged prostate, comprising alba Linne) extract or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide a method for preventing or treating prostatic hyperplasia comprising administering the pharmaceutical composition to a subject.
  • Still another object of the present invention is to provide a food composition for preventing or improving prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.
  • Still another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.
  • composition comprising the extract of the extract from the extract of the present invention, the extract from the extract, or the mixture of the extract from the extract from the extract, and the extract from the extract, the prostate hypertrophy is similar to or better than that treated with finasteride, which is used as an agent for prostatic hyperplasia. It is effective to prevent, improve and treat.
  • composition of the present invention is derived from natural products, it can be safely used without side effects in the prevention, treatment and improvement of prostate hyperplasia.
  • NC means normal control group and BPH means prostatic hyperplasia control group, Finasteride treatment group was used as a positive control. All values are expressed as mean ⁇ SEM. The statistical significance of each result was confirmed by ANOVA test, and different subscripts represented by a, b, c or d mean significant difference at p ⁇ 0.01.
  • Morus alba Linne provides a pharmaceutical composition for the prevention or treatment of enlarged prostate, comprising an extract or a fraction thereof as an active ingredient.
  • the present invention is Morus alba Linne) extract or a fraction thereof as an active ingredient provides a prophylactic or therapeutic use of prostatic hyperplasia.
  • the mixture of the extract of Achul extract in the extract of the lettuce extract effectively reduces the prostate weight of the experimental animal inducing prostatic hyperplasia, so that the extract or mixture of extracts of the therapeutic agent of prostatic hyperplasia It was confirmed that it can be used as an active ingredient.
  • Morus " alba Linne) means a medicinal herb made from the mulberry of the Mulberry family or from the roots of the same plant. Generally, the roots are peeled, peeled and sunk until they germinate until late spring and next spring germination. Although it has been known that it has some peculiar smell and little taste, the epidermis is known to be effective for chest pain caused by chronic bronchitis, coronary atherosclerosis, etc., but the therapeutic effect of prostate-related diseases is not known, and it is known to the present inventors. Was first identified.
  • the lettuce skin may be purchased commercially, or may be used collected or grown in nature.
  • extract refers to extracts themselves, such as extracts obtained by extracting the baekbaekpi, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, crude or purified products of the extracts, or mixtures thereof. And extracts of all formulations that can be formed using extracts.
  • the method of extracting the baekbaekpi is not particularly limited, and may be extracted according to a method commonly used in the art.
  • the type of extraction solvent used to extract the baekryepi is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent may include water, alcohols having 1 to 4 carbon atoms or mixed solvents thereof, and these may be used alone or in combination of one or more thereof. Specific 70% ethanol may be used, but is not limited thereto.
  • fraction refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising several various components.
  • the fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting the baekryepi of the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • the kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Nonpolar solvents such as hexane, ethyl acetate, chloroform and dichloromethane; Or a mixed solvent thereof. These may be used alone or in combination of one or more, but are not limited thereto.
  • extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.
  • prostate hyperplasia refers to a disease in which the prostate enlarges abnormally and makes urinary tract difficult to urinate, and the prostate is enlarged and diagnosed as prostatic hyperplasia when accompanied by lower urinary tract symptoms.
  • Prostate hyperplasia is one of the most common diseases occurring in middle-aged men. It is known that 50%, 60% in 60s, and 70% in 70s usually start in their 40s.
  • the pharmaceutical composition for preventing or treating prostatic hyperplasia of the present invention may further include ahyeol extract or a fraction thereof as an active ingredient.
  • curcumae Rhizoma refers to a medicinal herb prepared by drying the rhizome of Curcuma zedoaria , Curcuma phaeocaulis Val., Curcuma kwangsiensis SG Lee et CF Liang, or Curcuma wenyujin YH Chen et C. Ling. It is 2 ⁇ 8cm long and 1.5 ⁇ 4cm in diameter and has an outer shape of oval, long round, conical or long fusiform. It has a slightly peculiar smell and the taste is known to be bitter and spicy. Although effects on amenorrhea, menstrual cramps, indigestion, bruises and the like are known, the therapeutic effect of prostate-related diseases is not known and was first identified by the present inventors.
  • the outbreak may be purchased commercially, or may be used collected or grown in nature.
  • prevention refers to all acts that inhibit or retard prostatic hyperplasia by administration of the pharmaceutical composition of the present invention, which includes an extract of the baekryepi or fractions thereof, and further comprising an extract or fractions thereof. it means.
  • treatment means any action in which an enlarged or beneficially improved prostate enlargement is administered by administration of the pharmaceutical composition.
  • the pharmaceutical composition of the present invention may include 0.0001 to 50% by weight of the baekryepi extract relative to the weight of the total composition, specifically may include 0.01 to 10% by weight, but is not limited thereto.
  • the extract may be included in 0.0001 to 50% by weight, specifically may include 0.01 to 10% by weight, but is not limited thereto.
  • the pharmaceutical composition of the present invention may include the extract of baekryepi and Achul extract in a weight ratio of 0.001 to 5: 0.001 to 5, specifically may be included in a weight ratio of 0.001 to 3: 0.001 to 3, more specifically 1: It may include a weight ratio of 1, but is not limited thereto.
  • the pharmaceutical composition of the present invention may include a mixture of lettuce extract alone or amalgam extract, and may also include an extract of a mixture of lettuce extract and amalgam, and may specifically include a mixture of lettuce extract alone or amalgam extract. This is not restrictive.
  • the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, which carrier may comprise a non-naturally occuring carrier. have.
  • compositions may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method.
  • pharmaceutically acceptable means to exhibit properties that are not toxic to cells or humans exposed to the composition.
  • the type of the carrier is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • ком ⁇ онентs such as antioxidants, buffers and / or bacteriostatic agents may be added and used, and diluents, dispersants, surfactants, binders, lubricants, and the like may be additionally added to provide a solution such as an aqueous solution, a suspension, an emulsion, or the like. It may be formulated into a use formulation, pills, capsules, granules or tablets.
  • the mode of administration of the pharmaceutical composition for preventing or treating prostatic hyperplasia according to the present invention is not particularly limited, and may be in accordance with a conventional method used in the art.
  • the composition may be administered by oral or parenteral administration.
  • the composition for preventing, ameliorating or treating the enlarged prostate of the present invention may be prepared in various formulations according to the desired administration mode.
  • Another aspect provides a method of preventing or treating enlarged prostate, comprising administering the pharmaceutical composition to a subject.
  • the definition of the enlarged prostate, prevention and treatment is as described above.
  • the term "administration” means the introduction of certain substances into an individual in a suitable manner.
  • the term "individual” means all animals, such as rats, mice, and livestock, including humans that may develop or may develop prostatic hyperplasia. As a specific example, it may be a mammal including a human.
  • the method for preventing or treating prostatic hyperplasia of the present invention comprises the step of administering a pharmaceutical composition comprising a lettuce extract or a fraction thereof, and further comprising a subcutaneous extract or a fraction thereof in a pharmaceutically effective amount to the individual. can do.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level refers to the sex, Factors including age, weight, health, type of disease, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, and rate of excretion, duration of treatment, combination or drug used and other medicines It can be easily determined by those skilled in the art according to factors well known in the art.
  • composition of the present invention may be administered in 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight based on solids. Dosing may include administering the recommended dose once daily, or in divided doses.
  • the route of administration and mode of administration of the composition are not particularly limited, and any route of administration can be reached as long as the composition comprising the composition can be reached at the desired site.
  • the composition may be administered through various routes, oral or parenteral, and non-limiting examples of the route of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal What is administered through intralateral or inhalation etc. are mentioned.
  • Another embodiment provides a food composition for preventing or improving prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.
  • the definition of the epidermis, extract, fraction, prostatic hyperplasia and prevention is as described above.
  • Food composition for preventing or improving the prostate hypertrophy of the present invention comprises an extract of the baekryepi or fractions thereof, and may further comprise ahyeol extract or fractions thereof as an active ingredient.
  • the term " improvement" means any action that at least reduces the parameters associated with the condition to be treated with the administration of the compositions of the present invention, eg the extent of symptoms.
  • the term "food” of the present invention meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.
  • the food composition of the present invention can be consumed on a daily basis, a high prostate hypertrophy improvement effect can be expected, and thus can be very useful for health promotion purposes.
  • the functional food is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, so that the bioregulatory function appears efficiently, high medical effect Means food.
  • Food for special health use Food for special health use, FoSHU
  • the term 'function (sex)' refers to obtaining a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body.
  • the food of the present invention may be prepared by a method commonly used in the art, and the preparation may be performed by adding raw materials and ingredients commonly added in the art.
  • the formulation of the food may be prepared without limitation as long as the formulation is recognized as a food.
  • Food composition of the present invention can be prepared in a variety of formulations, unlike the general drug has the advantage that there is no side effect that may occur when taking a long-term use of the drug as a food raw material, because the portability is excellent,
  • the food of the present invention can be taken as an adjuvant for enhancing the effect of improving the prostate enlargement.
  • the health food refers to foods having active health maintenance or promotion effect as compared to general foods
  • the health supplement food refers to foods for health supplementation purposes.
  • nutraceutical, health food, dietary supplement are used.
  • the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • the food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.
  • the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like.
  • additional ingredients may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like.
  • minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, valine and the like.
  • the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorant (such as tar pigment), colorant (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG glutamate, etc.), sweetener (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers It may include food additives.
  • the additive may be selected according to
  • An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame;
  • the ratio of the natural carbohydrate may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health beverage composition of the present invention.
  • the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like.
  • Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
  • Another embodiment provides a quasi-drug composition for the prevention or improvement of prostate hyperplasia comprising an extract of the epidermis or a fraction thereof as an active ingredient.
  • the quasi-drug composition for preventing or improving the prostate hypertrophy of the present invention may include an extract of the lettuce extract or a fraction thereof, and may further include an extract or an extract thereof as an active ingredient.
  • the term "quasi drug” refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, and has a weak action on the human body or does not directly act on the human body.
  • the quasi-drug may include external skin preparations and personal hygiene products.
  • the extract according to the present invention or a fraction thereof When the extract according to the present invention or a fraction thereof is used as an quasi-drug additive, the extract or a fraction thereof may be added as it is, or used together with other quasi-drug or quasi-drug components, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the intended use.
  • the external preparation for the skin is not particularly limited thereto, but may be prepared and used, for example, in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel.
  • the quasi-drug composition of the present invention may be included in various weight% if it can exhibit the effect of preventing or improving prostate hyperplasia, but specifically the extract or fractions of the present invention 0.01 to 100% by weight, more specifically, the total weight of the quasi-drug composition It may include 1 to 80% by weight.
  • Sangbaekpi (Scientific name: Morus alba Linne, herbal name: Mori Radicis Cortex) extract was prepared by the following method. After commercially available commercial white skin was pulverized, 10 L of 70% ethanol was added to 1 kg of ground matter. Thereafter, ultrasonic extraction was performed three times for 1 hour. The ultrasonic extract was filtered through an Advantec No. 2 (110 mm) filter paper to remove insoluble matters, and then concentrated under reduced pressure at 45 ° C. with a condenser equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 500 mL of purified water was added and suspended, and 146.4 g of an extract was obtained using a lyophilizer (yield 14.6%).
  • Curcumae Rhizoma extract was prepared by the following method. Commercially available extracts were obtained and ground, and then 10 L of 70% ethanol was added to 1 kg of the ground product. Thereafter, ultrasonic extraction was performed three times for 1 hour. The ultrasonic extract was filtered through an Advantec No. 2 (110 mm) filter paper to remove insoluble matters, and then concentrated under reduced pressure at 45 ° C. with a condenser equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 500 mL of purified water was added and suspended, and then 41.43 g of an extract was obtained using a lyophilizer (yield 4.14%).
  • Example 1-1 Measurement of prostate weight
  • a prostatic hypertrophy-induced control group was prepared by injecting 10 mg / kg TP (testosterone propionate) subcutaneously for 4 weeks.
  • the experimental group treated with each extract was prepared by orally administering the extract of the lettuce extract, Achul extract or a mixture of lettuce extract and Achul (1: 1) prepared at Example 1 one hour before TP injection at 100 mg / kg for 4 weeks. .
  • the mixture was prepared by mixing the extracted epidermis and buds in a solvent immediately before administration.
  • corn oil was injected subcutaneously.
  • Relative prostate weight Mean SD SEM P-value NC normal control
  • BPH prostatic hypertrophy control
  • Finasteride 0.0045 0.0003 0.0001 P ⁇ 0.01 1White Skin 0.0044 0.0004 0.0002 P ⁇ 0.01 2
  • the mixture of the extracts of the extracts of the extracts of the extract and the extracts of the prostate was more effective in reducing the weight of the prostate than the treatment of the extracts of the extracts or extracts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate, contenant un extrait de Morus alba Linnaeus et un extrait de rhizome de Curcuma et, plus précisément, une composition pharmaceutique, une composition alimentaire et une composition d'alicament destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate, toutes ces compositions contenant un extrait de Morus alba Linnaeus ou une fraction de celui-ci et un extrait de rhizome de Curcuma ou une fraction de celui-ci en tant que principes actifs ; et une méthode de prévention ou de traitement de l'hyperplasie bénigne de la prostate utilisant la composition pharmaceutique. La composition contenant, en tant que principe actif, un extrait de Morus alba Linnaeus, un extrait de rhizome de Curcuma ou un mélange d'un extrait de Morus alba Linnaeus et d'un extrait de rhizome de Curcuma selon la présente invention, présente un effet similaire ou identique, en termes de prévention, soulagement et traitement de l'hyperplasie bénigne de la prostate, à celui obtenu avec un traitement à base de finastéride, qui est utilisé en tant que médicament contre l'hyperplasie bénigne de la prostate. En outre, la composition de la présente invention est obtenue à partir d'un produit naturel, si bien qu'elle peut être utilisée en toute sécurité pour prévenir, traiter et soulager l'hyperplasie bénigne de la prostate sans effets secondaires.
PCT/KR2017/002001 2016-02-24 2017-02-23 Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus WO2017146486A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160022032A KR102043404B1 (ko) 2016-02-24 2016-02-24 상백피(Morus alba Linne) 추출물을 포함하는 전립선 비대증의 예방 또는 치료용 조성물
KR10-2016-0022032 2016-02-24

Publications (1)

Publication Number Publication Date
WO2017146486A1 true WO2017146486A1 (fr) 2017-08-31

Family

ID=59685383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002001 WO2017146486A1 (fr) 2016-02-24 2017-02-23 Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus

Country Status (2)

Country Link
KR (1) KR102043404B1 (fr)
WO (1) WO2017146486A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102413429B1 (ko) 2017-08-08 2022-06-28 주식회사 만도 브레이크 시스템용 피스톤 펌프
KR20190090910A (ko) 2018-01-26 2019-08-05 최윤식 나노화된 꿀벌 화분을 유효성분으로 포함하는 양성 전립선 비대증 개선용 조성물
KR102211313B1 (ko) 2019-01-17 2021-02-04 경희대학교 산학협력단 울금 및 정향의 혼합 추출물을 포함하는 전립선비대증의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259905C (zh) * 2003-08-05 2006-06-21 北京大学 姜黄素在制备治疗肺病的药物中的用途
KR101515533B1 (ko) * 2013-06-21 2015-04-29 고려대학교 산학협력단 상백피 추출물을 유효성분으로 함유하는 혈중 콜레스테롤 저하제 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259905C (zh) * 2003-08-05 2006-06-21 北京大学 姜黄素在制备治疗肺病的药物中的用途
KR101515533B1 (ko) * 2013-06-21 2015-04-29 고려대학교 산학협력단 상백피 추출물을 유효성분으로 함유하는 혈중 콜레스테롤 저하제 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEVI, B. ET AL.: "Morus Alba Linn: a Phytopharmacological Review", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 5, no. 2, 2013, pages 14 - 18, XP055134293 *
KIM, S. K. ET AL.: "Inhibitory Effect of Curcumin on Testosterone Induced Benign Prostatic Hyperplasia Rat Model", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 15, no. 380, 2015, pages 1 - 7, XP055328092 *
KOLLAR, P. ET AL.: "Prenylated Flavonoids from Morus Alba L. Cause Inhibition of Gl/S Transition in THP-1 Human Leukemia Cells and Prevent the Lipopolysaccharide-induced Inflammatory Response", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2013, no. 350519, 2013, pages 1 - 13, XP055413294 *

Also Published As

Publication number Publication date
KR20170100100A (ko) 2017-09-04
KR102043404B1 (ko) 2019-11-12

Similar Documents

Publication Publication Date Title
RU2500416C2 (ru) Композиции для предотвращения или облегчения желудочно-кишечных заболеваний
WO2012050396A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du foie
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2018174589A1 (fr) PROCÉDÉ POUR SOULAGER LA GINGIVITE ET LA PARODONTITE PAR ANTIBIOSE, ANTIOXYDATION, ANTI-INFLAMMATION, SUPPRESSION DE LA PERTE OSSEUSE PARODONTALE ET RÉGÉNÉRATION DE L'OS PARODONTAL AU MOYEN D'UN COMPLEXE D'EXTRAIT DE FEUILLE DE MORINGA OLEIFERA ET D'EXTRAIT D'EUCOMMIA ULMOIDES <i /><i />
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
JP2014015430A (ja) 深部体温上昇剤
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus
WO2012050398A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du poumon
WO2013100340A1 (fr) Composition comprenant un extrait de dendropanax morbiferus pour améliorer la fonction sexuelle masculine
WO2012050397A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein
WO2016167577A1 (fr) Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur
KR101624704B1 (ko) 탈모 또는 전립선 비대증의 예방, 치료 또는 개선용 약학 조성물 및 건강기능식품용 조성물
JP6369931B2 (ja) 抗肥満剤
JPH07119176B2 (ja) 抗活性酸素作用組成物並びにこれを有効成分とする抗活性酸素剤、食品、化粧料及び医薬品
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
KR101808944B1 (ko) 생강 추출물의 비극성 용매 분획물을 유효성분으로 포함하는 월경통 및 조기분만진통의 예방 및 치료용 약학적 조성물
KR101833776B1 (ko) 지모와 두릅의 복합 추출물을 함유하는 탈모 방지 및 발모 개선용 조성물
WO2017082501A1 (fr) Composition visant à prévenir ou traiter les troubles de la ménopause et contenant de l'extrait de tetragonia tetragonoides (pall.) kuntze
KR20180058997A (ko) 백발생성 억제 또는 흑모생성 촉진용 약학 조성물, 식품 조성물 및 그 제조방법
EP3995143A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
KR102014922B1 (ko) 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
KR20210003999A (ko) Agkistrodon piscivorous piscivorous로부터 유래된 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물
JP6063499B2 (ja) 生地黄、枸杞子、沈香、茯苓、高麗人蔘と蜂蜜の混合物を有効成分として含有する男性不妊予防および治療用薬学的組成物
WO2021040449A2 (fr) Composition pour la prévention ou le traitement du cancer comprenant un extrait mixte d'angelica gigas, d'aconitum carmichaeli debeaux et de zingiber officinale roscoe comme principe actif

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17756824

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17756824

Country of ref document: EP

Kind code of ref document: A1